8-K: Cellectar Biosciences Reports Q1 2026 Results, Secures Funding

Cellectar Biosciences announced positive Q1 2026 financial results, positive follow-on data for iopofosine I 131, and secured up to $140 million in financing.

Summary

• Cellectar Biosciences reported its financial results for the quarter ended March 31, 2026.
• The company announced positive 12-month follow-on data for iopofosine I 131 in relapsed/refractory Waldenstrm Macroglobulinemia (r/r WM).
• A financing of up to $140 million was completed to support the initiation of a confirmatory study of iopofosine I 131 in r/r WM and a subsequent U.S. FDA filing for accelerated approval.
• First patients were dosed in a Phase 1b dose-finding study for CLR 125 in triple-negative breast cancer, with early data expected mid-year 2026.
• The company reported a net loss of $5.7 million, or $1.33 per share, for the quarter.
• Cash and cash equivalents were $8.3 million as of March 31, 2026, excluding proceeds from the May financing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to strong clinical data, significant financing secured, and advancement of pipeline programs, despite the ongoing net loss typical for the industry.

Positives

• Positive 12-month follow-on data for iopofosine I 131 in r/r WM, showing a 61.8% major response rate (MRR) and a median duration of response (DoR) of 17.8 months.
• Overall response rate (ORR) of 83.6% and median progression-free survival (PFS) of 13.5 months for iopofosine I 131 in r/r WM.
• Completion of a financing of up to $140 million to support key regulatory milestones and potential commercialization of iopofosine I 131.
• Selection for presentation of iopofosine I 131 data at ASCO 2026.
• Enrollment of the first patient in the Phase 1b study of CLR 125 in triple-negative breast cancer.
• The company believes its cash balance, along with the May financing, is adequate to fund budgeted operations into Q2 2027.

Negatives

• Net loss of $5.7 million for the quarter ended March 31, 2026.
• Cash and cash equivalents decreased to $8.3 million from $13.2 million at the end of the previous quarter.
• Accumulated deficit of $274.8 million as of March 31, 2026.

Risks

• Uncertainties related to the ability to identify suitable collaborators, partners, licensees or purchasers for product candidates.
• Risks associated with entering into binding agreements for collaborations or partnerships.
• The need to raise additional capital to support operations.
• Potential for operations to be unfunded if capital raising efforts are unsuccessful.
• Drug discovery and development involve a high degree of risk.

Future Outlook

The company believes its current cash position, augmented by the May 2026 financing, will adequately fund its operations into the second quarter of 2027, including the initiation of the iopofosine I 131 confirmatory study in WM. Plans are advancing to initiate a Phase 3 confirmatory trial of iopofosine I 131 and file for accelerated approval with the U.S. FDA. Work continues with the EMA for a Conditional Marketing Approval for iopofosine I 131 in WM.

Management Comments

• "The first part of 2026 was a pivotal period for Cellectar as we executed across our pipeline and capital strategies to position the company for value creation."
• "With the support of industry-leading healthcare focused investors, we successfully completed a financing of up to $140 million, providing the necessary resources to advance iopofosine through key U.S. regulatory milestones and potential commercialization."
• "The recently reported positive 12-month follow-on data from our CLOVER WaM study reinforce our confidence that iopofosine can provide meaningful patient benefits and meet regulatory expectations, supporting our plans to initiate a Phase 3 confirmatory study and file for accelerated approval with the FDA."
• "In parallel, we expanded our radio-conjugate pipeline with the enrollment of the first patients in our Phase 1b study of CLR 125 in triple negative breast cancer, a challenging solid tumor cancer with a substantial unmet medical need."
• "Together, these advances underscore the strength of our radiopharmaceutical platform and potential to deliver meaningful new treatment options to patients battling a variety of difficult-to-treat cancers."

Industry Context

StockSavvy.ai notes that Cellectar Biosciences' progress in advancing its radiopharmaceutical pipeline, particularly with iopofosine I 131 for Waldenstrm Macroglobulinemia and CLR 125 for triple-negative breast cancer, aligns with the broader industry trend towards targeted therapies and personalized medicine in oncology. The successful financing further supports the company's ability to navigate the complex and capital-intensive drug development process.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from securing significant financing and positive clinical data, potentially increasing future value.
• Employees: Continued employment and potential for growth as the company advances its pipeline.
• Creditors: Improved financial stability due to the capital raise, reducing short-term risk.

Next Steps

• Initiate a Phase 3 confirmatory study of iopofosine I 131 in WM.
• File for accelerated approval with the U.S. FDA for iopofosine I 131.
• Continue to work with the EMA to file for Conditional Marketing Approval (CMA) for iopofosine I 131.
• Provide dosimetry, safety and efficacy updates for the CLR 125 study in the second quarter and throughout the balance of 2026.
• The Phase 3 study for iopofosine I 131 is projected to have full patient enrollment within 18-24 months of the first patient admitted.

Key Dates

Recommendation

The company has demonstrated positive clinical progress and secured crucial funding, which are significant positives. However, it continues to operate at a net loss, and the path to commercialization involves substantial risks and further capital requirements. A 'hold' recommendation reflects the balance of promising developments against the inherent risks and long development timelines in the biopharmaceutical sector.

Keywords

Cellectar Biosciences, Iopofosine I 131, Waldenstrm Macroglobulinemia, CLR 125, Triple Negative Breast Cancer, Clinical Trial, Biopharmaceutical, FDA Filing